Total Valuation
Takeda Pharmaceutical Company has a market cap or net worth of €60.12B. The enterprise value is €85.30B.
Market Cap€60.12B
Enterprise Value€85.30B
Share Statistics
Takeda Pharmaceutical Company has 3,204,437,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,204,437,000
Owned by Insiders0.12%
Owned by Institutions0.09%
Financial Efficiency
Takeda Pharmaceutical Company’s return on equity (ROE) is 0.03 and return on invested capital (ROIC) is 3.11%.
Return on Equity (ROE)0.03
Return on Assets (ROA)0.01
Return on Invested Capital (ROIC)3.11%
Return on Capital Employed (ROCE)0.04
Revenue Per Employee101.59M
Profits Per Employee-3.23M
Employee Count47,029
Asset Turnover0.31
Inventory Turnover1.67
Valuation Ratios
The current PE Ratio of Takeda Pharmaceutical Company is 27.2. Takeda Pharmaceutical Company’s PEG ratio is 0.53.
PE Ratio27.2
PS Ratio1.94
PB Ratio1.19
Price to FCF14.77
Price to Operating Cash Flow13.42
PEG Ratio0.53
Income Statement
In the last 12 months, Takeda Pharmaceutical Company had revenue of 4.78T and earned 203.33B in profits. Earnings per share was 63.91.
Revenue4.78T
Gross Profit2.44T
Operating Income573.04B
Pretax Income275.88B
Net Income203.33B
EBITDA1.38T
Earnings Per Share (EPS)63.91
Cash Flow
In the last 12 months, operating cash flow was 832.59B and capital expenditures -385.11B, giving a free cash flow of 447.47B billion.
Operating Cash Flow832.59B
Free Cash Flow447.47B
Free Cash Flow per Share139.64
Dividends & Yields
Takeda Pharmaceutical Company pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.33
52-Week Price Change60.75%
50-Day Moving Average16.16
200-Day Moving Average14.73
Relative Strength Index (RSI)65.53
Average Volume (3m)52.00
Important Dates
Takeda Pharmaceutical Company upcoming earnings date is Jan 28, 2027, Before Open (Confirmed).
Last Earnings DateOct 29, 2026
Next Earnings DateJan 28, 2027
Ex-Dividend Date―
Financial Position
Takeda Pharmaceutical Company as a current ratio of 1.27, with Debt / Equity ratio of 61.70%
Current Ratio1.27
Quick Ratio0.70
Debt to Market Cap0.53
Net Debt to EBITDA3.13
Interest Coverage Ratio1.51
Taxes
In the past 12 months, Takeda Pharmaceutical Company has paid 72.27B in taxes.
Income Tax72.27B
Effective Tax Rate0.26
Enterprise Valuation
Takeda Pharmaceutical Company EV to EBITDA ratio is 9.86, with an EV/FCF ratio of 21.64.
EV to Sales2.84
EV to EBITDA9.86
EV to Free Cash Flow21.64
EV to Operating Cash Flow13.02
Balance Sheet
Takeda Pharmaceutical Company has €454.40B in cash and marketable securities with €4.58T in debt, giving a net cash position of -€4.12T billion.
Cash & Marketable Securities€454.40B
Total Debt€4.58T
Net Cash-€4.12T
Net Cash Per Share-€1.29K
Tangible Book Value Per Share-€463.43
Margins
Gross margin is 62.49%, with operating margin of 11.99%, and net profit margin of 4.26%.
Gross Margin62.49%
Operating Margin11.99%
Pretax Margin5.77%
Net Profit Margin4.26%
EBITDA Margin28.80%
EBIT Margin13.71%
Analyst Forecast
The average price target for Takeda Pharmaceutical Company is €38.51, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€38.51
Price Target Upside146.86% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast-4.28%
EPS Growth Forecast12.36%